NLRP3 and acute kidney injury: In conclusion, M-18C was able to reduce the release of TNF-α and IL-1β by inhibiting the expression of NLRP3 and ASC proteins, repairing the intestinal barrier, and regulating the intestinal flora and serum metabolism, thereby alleviating LPS-induced AKI.